IMFINZI® (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefit in Unresectable, Stage III Lung Cancer

IMFINZI® (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefit in Unresectable, Stage III Lung Cancer: https://ift.tt/2Q2BEnJ Read more... https://ift.tt/2Ife848